| News
VectivBio raises 125 million US dollars in stock sale
21.10.2022
VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross proceeds of around 125 million US dollars from this. The fresh capital is intended to help further develop the company’s product candidate for severe rare gastrointestinal diseases.
The Basel-based biotechnology firm VectivBio Holding AG has raised around 125 million US dollars after selling off 16,700,000 ordinary shares. These were offered for purchase at a price of 7.50 US dollars per share. Details of this were recently announced by the company as part of a press release.
Advancing clinical development
According to the information provided, VectivBio intends to put the net proceeds from the stock sale and available cash funds towards the clinical development and pre-commercial activities in connection with the lead product candidate as well as for general corporate purposes.
The lead product candidate, apraglutide, is a next-generation, long-acting, glucagon-like peptide (GLP)-2 analog. It is being developed for a number of rare gastrointestinal diseases, such as short bowel syndrome with intestinal failure (SBS-IF) and Acute Graft-Versus-Host Disease (aGVHD), where GLP-2 can play a central role in addressing the pathophysiology of the disease.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...
Read More
Record figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...
Read More
Noema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....
Read More
Why CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...
Read More
Basel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...
Read More
Ariceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...
Read More
